Lee GY, et al. (2014) PIASy-Mediated Sumoylation of SREBP1c Regulates Hepatic Lipid Metabolism upon Fasting Signaling. Mol Cell Biol 34, 926-38 24379443

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

K98-sm - SREBP-1 iso1 (rat) ▲

Modsite: FSPGPGIkEEPVPLT SwissProt Entrez-Gene Orthologous residues SREBP‑1 (human): K123‑sm, SREBP‑1 iso3 (human): K99‑sm, SREBP‑1 iso4 (human): K153‑sm, SREBP‑1 (mouse): K121‑sm, SREBP‑1 iso4 (mouse): ‑, SREBP‑1 (rat): K122‑sm, SREBP‑1 iso1 (rat): K98‑sm Characterization Methods used to characterize site in vivo:  electrophoretic mobility shift, immunoprecipitation, modification-specific antibody, multiple reaction monitoring (MRM), western blotting Relevant cell lines - cell types - tissues:  COS (fibroblast), HeLa (cervical), hepatocyte Cellular systems studied:  cell lines, primary cells Species studied:  green monkey, human, mouse Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes SUMO LIGASE PIAS4 (human) siRNA inhibition of enzyme, transfection of wild-type enzyme UBIQUITIN LIGASE UBC9 (human) transfection of wild-type enzyme DESUMOYLASE SENP2 (human) transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes SENP1 (human) no change compared to control SENP3 (human) no change compared to control siRNA decrease PIASY (shRNA) glucagon increase NKH_477 increase H-89 glucagon inhibit treatment-induced increase H-89 NKH_477 inhibit treatment-induced increase Downstream Regulation Effect of modification (function):  protein degradation, sumoylation, ubiquitination Effect of modification (process):  transcription, inhibited

S308-p - SREBP-1 iso1 (rat) ▲

Modsite: IEKRYRSsINDKIVE SwissProt Entrez-Gene Orthologous residues SREBP‑1 (human): S338‑p, SREBP‑1 iso3 (human): S314‑p, SREBP‑1 iso4 (human): S368‑p, SREBP‑1 (mouse): S332‑p, SREBP‑1 iso4 (mouse): S266‑p, SREBP‑1 (rat): S332‑p, SREBP‑1 iso1 (rat): S308‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Relevant cell lines - cell types - tissues:  COS (fibroblast), hepatocyte Cellular systems studied:  cell lines, primary cells Species studied:  green monkey, mouse Enzymes shown to modify site in vitro:  Type Enzyme KINASE PKACA (human) Downstream Regulation Effect of modification (function):  protein degradation, sumoylation, ubiquitination Effect of modification (process):  transcription, inhibited